Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:09

Coagulation

8.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

68
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
68
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

11.6K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
11.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodological Definition and Validation of the Intracranial Pressure-End-Tidal CO2 Slope (IESlope): Characterization and Clinical Relevance in Traumatic Brain Injury.

Journal of neurosurgical anesthesiology·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Dual-opioid spinal anaesthesia in enhanced recovery after caesarean section: effects on postoperative opioid requirement and maternal recovery.

Journal of anesthesia, analgesia and critical care·2026
Same author

Perioperative antithrombotic management in elective neurosurgery: a survey from the Lombardia Neurocritical Care Network, Italy.

Minerva anestesiologica·2026
Same author

Rethinking the sphenoparietal sinus: implications for lesser sphenoid wing dural arteriovenous fistulas. Illustrative cases.

Journal of neurosurgery. Case lessons·2026
Same author

Third ventricle cavernous malformations: Diagnostic pitfalls and optimal surgical strategies - Scoping review with institutional series.

Clinical neurology and neurosurgery·2026

Related Experiment Video

Updated: Oct 16, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

921

Coagulopathy and COVID-19.

Ferdinando Luca Lorini1, Maria Di Matteo1, Paolo Gritti1

  • 1Dipartimento di Anestesia e Terapia Intensiva, Ospedale Papa Giovanni XXIII, Bergamo, Italia.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|October 15, 2021
PubMed
Summary

COVID-19 associated coagulopathy (CAC) involves hypercoagulability, leading to organ damage. Heparin shows promise for treating CAC due to its anticoagulant, antiviral, and anti-inflammatory effects, though optimal dosage is undetermined.

Keywords:
COVID-19CoagulopathyD-dimerimmunothrombosis

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

740
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.0K

Related Experiment Videos

Last Updated: Oct 16, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

921
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

740
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.0K

Area of Science:

  • Hematology
  • Infectious Diseases
  • Pathophysiology

Background:

  • SARS-CoV-2 infection frequently causes thrombotic events (COVID-19 associated coagulopathy).
  • CAC is characterized by high D-dimer and fibrinogen levels, distinct from other coagulopathies.
  • The pathogenesis involves complex interactions between inflammation, coagulation, immunothrombosis, and endothelial dysfunction.

Purpose of the Study:

  • To explore the mechanisms of COVID-19 associated coagulopathy (CAC).
  • To investigate the potential therapeutic role of heparin in managing CAC.
  • To highlight the unique features of CAC compared to other coagulation disorders.

Main Methods:

  • Literature review of coagulative alterations in SARS-CoV-2 infection.
  • Analysis of the interplay between inflammatory and coagulation systems.
  • Examination of the role of neutrophils, complement, fibrinolysis, platelets, and endothelial function.

Main Results:

  • CAC is a unique coagulopathy driven by thrombo-inflammation and immunothrombosis.
  • Mechanisms include inflammatory cytokines, complement activation, fibrinolytic system alterations, platelet dysfunction, and endothelial dysfunction.
  • Heparin exhibits potential anticoagulant, antiviral, and anti-inflammatory effects in CAC.

Conclusions:

  • COVID-19 associated coagulopathy is a complex condition with unique pathophysiological features.
  • Heparin presents a promising therapeutic option for CAC, warranting further investigation into optimal dosing regimens.
  • Understanding CAC mechanisms is crucial for mitigating SARS-CoV-2-related organ damage.